Ultragenyx Pharmaceutical Quarterly Income Statement
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical revenue and earnings
In the quarter ended Jun 30, 2026, Ultragenyx Pharmaceutical generated $214.0 million in revenue, up 28.1% from the same quarter a year earlier. Ultragenyx Pharmaceutical reported a net loss of $92.0 million, compared with a loss of $115.0 million a year earlier. Operating margin was -35.0%.
Diluted earnings per share came in at -$0.90.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 214.00M | 136.00M | 207.28M | 159.93M | 167.00M | 139.00M | 164.65M | 139.49M | 147.03M | 108.83M | 127.14M | 98.05M |
| Revenue growth (YoY) | +28.14% | -2.16% | +25.89% | +14.65% | +13.59% | +27.72% | +29.50% | +42.27% | +35.75% | +8.30% | +23.02% | +8.10% |
| Research & Development | 167.00M | 187.00M | 203.28M | 216.21M | 165.00M | 166.00M | 187.90M | 170.11M | 161.50M | 178.49M | 160.11M | 157.25M |
| Selling, General & Admin | 88.00M | 88.00M | 87.94M | 86.62M | 87.00M | 87.00M | 81.89M | 80.35M | 80.60M | 78.16M | 77.03M | 74.92M |
| Operating Income | -75.00M | -169.00M | -113.28M | -170.89M | -108.00M | -143.00M | -122.31M | -131.99M | -116.36M | -165.35M | -121.84M | -145.10M |
| Other Income (Expense) | 1.00M | — | -934.00K | -1.04M | 2.00M | 837.00K | -4.64M | 3.08M | -1.83M | -1.60M | 1.38M | -699.00K |
| Pretax Income | -91.00M | -184.00M | -127.69M | -179.54M | -114.00M | -150.00M | -132.82M | -133.21M | -130.74M | -170.23M | -127.43M | -159.00M |
| Income Tax | 1.00M | 1.00M | 870.00K | 873.00K | 1.00M | 1.00M | 384.00K | 303.00K | 858.00K | 455.00K | -3.88M | 650.00K |
| Net Income | -92.00M | -185.00M | -128.56M | -180.41M | -115.00M | -151.00M | -133.20M | -133.52M | -131.60M | -170.68M | -123.55M | -159.65M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.90 | -1.84 | -1.28 | -1.81 | -1.17 | -1.57 | -1.34 | -1.40 | -1.52 | -2.03 | -1.44 | -2.23 |
| EPS (Diluted) | -0.90 | -1.84 | -1.28 | -1.81 | -1.17 | -1.57 | -1.34 | -1.40 | -1.52 | -2.03 | -1.44 | -2.23 |
| Shares Outstanding (Basic) | 101.90M | 100.60M | — | 99.77M | 98.50M | 96.30M | — | 95.49M | 86.58M | 84.29M | — | 71.66M |
| Shares Outstanding (Diluted) | 101.90M | 100.60M | — | 99.77M | 98.50M | 96.30M | — | 95.49M | 86.58M | 84.29M | — | 71.66M |
| EBITDA | -67.00M | -161.00M | -104.50M | -162.68M | -99.00M | -134.00M | -112.77M | -123.23M | -107.50M | -156.50M | -113.63M | -137.91M |
| Operating Margin | -35.05% | -124.26% | -54.65% | -106.85% | -64.67% | -102.88% | -74.28% | -94.62% | -79.14% | -151.93% | -95.83% | -147.98% |
| Net Margin | -42.99% | -136.03% | -62.02% | -112.81% | -68.86% | -108.63% | -80.90% | -95.71% | -89.51% | -156.83% | -97.17% | -162.82% |
This table shows 12 quarterly periods of Ultragenyx Pharmaceutical's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RARE's reporting calendar. What is a income statement?